Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: As cancer center funds are allocated toward several resources, clinical trial offices and the clinical trial infrastructure is constantly scrutinized. It has been shown that 20% of clinical trials fail to achieve their accrual goal and in an institutional level several trials are open with poor accrual. We sought to identify factors that are associated with clinical trial accrual and develop a model to predict clinical trial accrual. METHODS AND MATERIAL: We identified all clinical trials from 1999 to 2015 at UT Health Cancer Center San Antonio. We included observational as well as interventional clinical trials. We collected several variables such as type of study, type of malignancy, trial phase, PI of study. RESULTS: In total we included 297 clinical trials. We identified several factors to be associated with clinical trial accrual (Sponsor type, trial phase, disease category, type of trial, disease state and whether the trial involved a new investigational agent). We developed a predictive model with an AUC of 0.65 that showed that observational, interventional, industry-sponsored trials and trials authored by the local PI were more likely to achieve their accrual goal. CONCLUSION: We were able to identify several factors that were significantly associated with clinical trial accrual. Based on these factors we developed a prediction model for clinical trial accrual. We believe that use of this model can help improve our cancer centers clinical trial portfolio and help in fund allocation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
- Date Crossref
- 01/09/2019
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Colorado Health Department of Hematology/Oncology pays non établi dans la noticeÉtablissement de santé
-
University of Colorado Colorado Springs pays non établi dans la noticeUniversité ou école supérieure
-
The University of Texas at San Antonio Health Science Center pays non établi dans la noticeUniversité ou école supérieure
-
Houston Methodist pays non établi dans la noticeÉtablissement de santé
-
The University of Texas Health Science Center at Houston pays non établi dans la noticeUniversité ou école supérieure
-
University of Texas Health Science Center San Antonio Department of Epidemiology and Biostatistics pays non établi dans la noticeUniversité ou école supérieure
-
Department of Medicine pays non établi dans la noticeInstitution
Department of Hematology/Oncology — University of Colorado Health, University of Colorado Colorado Springs et The University of Texas at San Antonio Health Science Center, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.